Superior therapeutic efficacy of N-L-leucyl-doxorubicin versus doxorubicin in human melanoma xenografts correlates with higher tumour concentrations of free drug

European Journal of Cancer

Volumn 35, Issue 7, 1999, Pages 1143-1149

  Breistol K ^a   Hendriks, H R ^b   Fodstad, Ø ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Anthracyclines; Antitumour activity; AUC; Doxorubicin; HPLC; Human tumour xenograft; Melanoma; N L leucyl doxorubicin; Nude mice; Pharmacokinetics

Indexed keywords

DOXORUBICIN; LEURUBICIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; MELANOMA; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; TREATMENT OUTCOME; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOXORUBICIN; HUMANS; MELANOMA; MICE; MICE, INBRED BALB C; PRODRUGS; SKIN NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0001354236     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(99)00074-X     Document Type: Article

References (31)

1. Masquelier M., Baurain R., Trouet A. Amino acid and dipeptide derivatives of daunorubicin. 1. Synthesis, physicochemical properties, and lysosomal digestion. J. Med. Chem. 23(11):1980;1166-1170.
2. Baurain R., Masquelier M., Deprez-De Campeneere D., Trouet A. Amino acid and dipeptide derivatives of daunorubicin. 2. Cellular pharmacology and antitumor activity on L1210 leukemic cells in vitro and in vivo. J. Med. Chem. 23(11):1980;1171-1174.
3. Trouet A., Masquelier M., Baurain R., Deprez-De Campeneere D. A covalent linkage between daunorubicin and proteins that is stable in serum and reversible by lysosomal hydrolases, as required for a lysosomotropic drug-carrier conjugate. in vitro and in vivo studies Proc. Natl. Acad. Sci. 79(2):1982;626-629.
4. Mueller B.M. Different roles for plasminogen activators and metalloproteinases in melanoma metastasis. Curr. Topics in Microbiol. & Immunol. 213:1996;65-80.
5. Yoshii A., Kageshita T., Tsushima H., Ono T. Clinical relevance of cathepsin B-like enzyme activity and cysteine proteinase inhibitor in melanocytic tumours. Arch. Dermatol. Res. 287(2):1995;209-213.
6. Boike G., Lah T., Sloane B.F.et al. A possible role for cysteine proteinase and its inhibitors in motility of malignant melanoma and other tumour cells. Melanoma Res. 1(5-6):1992;333-340.
7. Sloane B.F., Rozhin J., Johnson K., Taylor H., Crissman J.D., Honn K.V. Cathepsin B: association with plasma membrane in metastatic tumors. Proc. Natl. Acad. Sci. 83(8):1986;2483-2487.
8. Boven E., Hendriks H.R., Erkelens C.A.M., Pinedo H.M. The anti-tumor effects of the prodrug N-L-leucyl-doxorubicin and vinblastine-isoleucinate in human ovarian cancer xenografts. Br. J. Cancer. 66:1992;1044-1047.
9. Breistøl K., Hendriks H.R., Berger D.P., Langdon S.P., Fiebig H.H., Fodstad Ø The antitumour activity of the prodrug N-L-leucyl-doxorubicin and its parent compound doxorubicin in human tumour xenografts. Eur. J. Cancer. 34(10):1998;1602-1606.
10. Deprez-De Campeneere D., Baurain R., Trouet A. Accumulation and metabolism of new anthracycline derivatives in the heart after i.v. injection into mice. Cancer Chemother. Pharmacol. 8(2):1982;193-197.
11. de Jong J., Klein I., Bast A., van der Vijgh W.J. Analysis and pharmacokinetics of N-L-leucyldoxorubucin and metabolites in tissues of tumor-bearing BALB/c mice. Cancer Chemother. Pharmacol. 31(2):1992;156-160.
12. Zbinden G., DeCampeenere D., Baurain R. Preclinical assessment of the cardiotoxic potential of anthracycline antibiotics. N-L-leucyl-doxorubicin Arch. Toxicol. Suppl. 14:1991;107-117.
13. Jaenke R.S., Deprez-DeCampeneere D., Trouet A. Cardiotoxicity and comparative pharmacokinetics of six anthracyclines in the rabbit. Cancer Res. 40(10):1980;3530-3536.
14. Fodstad Ø., Aamdal S., McMenamin M., Nesland J.M., Pihl A. A new experimental metastasis model in athymic nude mice, the human malignant melanoma LOX. Int. J. Cancer. 41:1988;442-449.
15. Fodstad Ø., Aamdal S., Pihl A., Boyd M.R. Activity of mitozolomide (NSC 353451), a new imidazotetrazine, against xenografts from human melanomas, sarcomas, and lung and colon carcinomas. Cancer Res. 45:1985;1778-1786.
16. Shoemaker R.H., Dykes D.J., Plowman J.et al. Practical spontaneous metastasis model for in vivo therapeutic studies using a human melanoma. Cancer Res. 51:1991;2837-2841.
17. Godal A., Fodstad Ø., Morgan A.C., Pihl A. Human melanoma cell lines showing striking inherent differences in sensitivity to immunotoxins containing holotoxins. J. Natl. Cancer Inst. 77:1986;1247-1253.
18. Boven E., Winograd B., Berger D.P.et al. Phase II preclinical drug screening in human tumor xenografts. a first European multicenter collaborative study Cancer Res. 52:1992;5940-5947.
19. Langdon S.P., Hendriks H.R., Braakhuis B.J.et al. Preclinical phase II studies in human tumor xenografts. a European multicenter follow-up study Ann. Oncol. 5(5):1994;415-422.
20. Boven E., Winograd B., Fodstad Ø., Lobbezoo M.W., Pinedo H.M. Preclinical phase II studies in human tumor lines. a European multicenter study Eur. J. Cancer Clin. Oncol. 24(3):1988;567-573.
21. Maessen P.A., Pinedo H.M., Mross K.B., van der Vijgh W.J. New method for the determination of doxorubicin, 4′-epidoxorubicin and all known metabolites in cardiac tissue. J. Chromatogr. 424(1):1988;103-110.
22. van der Vijgh W.J., Maessen P.A., Pinedo H.M. Comparative metabolism and pharmacokinetics of doxorubicin and 4′-epidoxorubicin in plasma, heart and tumor of tumor-bearing mice. Cancer Chemother. Pharmacol. 26(1):1990;9-12.
23. Maessen P.A., Mross K.B., Pinedo H.M., van der Vijgh W.J. Improved method for the determination of 4′-epidoxorubicin and seven metabolites in plasma by high-performance liquid chromatography. J. Chromatogr. 417(2):1987;339-346.
24. Boven E., de Jong J., Kuiper C.M., Bast A., van der Vijgh W.J. Relationship between the tumor tissue pharmacokinetics and the antiproliferative effects of anthracyclines and their metabolites. Eur. J. Cancer. 32A(8):1996;1382-1387.
25. Bielack S.S., Erttmann R., Winkler K., Landbeck G. Doxorubicin. effect of different schedules on toxicity and anti-tumor efficacy Eur. J. Cancer Clin. Oncol. 25(5):1989;873-882.
26. Legha S.S., Benjamin R.S., Mackay B.et al. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann. Intern. Med. 96(2):1982;133-139.
27. Ferrans V.J., Clark J.R., Zhang J., Yu Z.X., Herman E.H. Pathogenesis and prevention of doxorubicin cardiomyopathy. Tsitologiia. 39(10):1997;928-937.
28. Gaudin P.B., Hruban R.H., Beschorner W.E.et al. Myocarditis associated with doxorubicin cardiotoxicity. Am. J. Clin. Pathol. 100(2):1993;158-163.
29. de Jong J., Geijssen G.J., Munniksma C.N., Vermorken J.B., van der Vijgh W.J. Plasma pharmacokinetics and pharmacodynamics of a new prodrug N-L-leucyldoxorubicin and its metabolites in a phase I clinical trial. J. Clin. Oncol. 10(12):1992;1897-1906.
30. Canal P., Robert J., Ramon M.et al. Human pharmacokinetics of N-L-leucyl-doxorubicin, a new anthracycline derivative, and its correlation with clinical toxicities. Clin. Pharmacol. Ther. 51(3):1992;249-259.
31. Bennis S., Garcia C., Robert J. Aspects of the cellular pharmacology of N-L-leucyldoxorubicin in human tumor cell lines. Biochem. Pharmacol. 45(9):1993;1929-1931.